EUCTR2019-001825-28-GB进行中（未招募）1 期
Mesoangioblast-mediated exon 51 skipping for genetic correction of dystrophin, based upon a single injection in individual skeletal muscles of five non ambulant patients affected by Duchenne Muscular Dystrophy: a non randomized, open label, phase I/IIa study. - Mesoangioblast-based gene therapy for Duchenne Muscular Dystrophy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Age between 12 and 16 years at time of study entry, provided that participants matching the eligibility criteria can be identified. Otherwise patients of progressively younger age may be recruited up to a minimum age of 8 years.
- •2.Non-ambulant at the time of recruitment.
- •3.Confirmed diagnosis of DMD with documented exon 51 skippable mutations in dystrophin gene.
- •4.Progression of muscle degeneration = to 50% reduction of muscle mass as determined by quantitative MRI (grade 2: Kinali et al. 2011).
- •5.Written informed consent of caregivers of DMD patients and patient’s assent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test.
- •2.Presence of immune deficiency, neoplastic or autoimmune disease (based on clinical history).
- •3.Bleeding disorder.
- •4.Any known allergies to products likely to be used in the study.
- •5.Prior or ongoing medical condition (e.g. concomitant illness, psychiatric condition, behavioural disorder, drug abuse), medical history, physical findings, or laboratory abnormality that, in the investigator’s opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
- •6.Ongoing participation in any other therapeutic clinical trial or treatment with exon skipping oligonucleotides. Use of steroids is considered standard care, as well as concomitant medications (e.g. B blockers, ACEI, ARBs, vitamin D, bisphosphonates) and therefore permitted.
- •7.FS (fraction shortening) < 28% or ECG finding significant for underlying cardiac impairment.
- •8.Pulmonary function tests assessed by spirometry (if cooperative) of FEV1 and FVC <30% of the predicted values. If unable, pulse oximetry < 95 % in room air.
- •9.Change of medication related to DMD within last 3 months with the exception of adjustment based on weight gain of current medications.
- •10.Presence of severe scoliosis (curve >50°).
- •11.Presence of significant impairment of renal or hepatic function.
研究者
相似试验
招募中
不适用
Identification of candidate gene for pathologic myopia in Korean using exome wide association studyKCT0006735Yonsei University Health System, Severance Hospital250
尚未招募
Unknown
iquid biopsy in metastatic brain tumoursCTRI/2024/07/071572Exsegen Genomics Research Pvt Ltd
招募中
不适用
iquid biopsy in brain tumoursCTRI/2021/09/036861Exsegen Genomics Research Pvt Ltd
招募中
不适用
Assess the mtDNA mutation load in mesoangioblasts of mtDNA mutation carriersmitochondrial muscle diseasemitochondrial myopathy10028302NL-OMON49928niversiteit Maastricht30
已完成
不适用
Assess the mtDNA mutation load in mesoangioblasts of mtDNA mutation carriersmitochondrial myopathymitochondrial muscle disease100274241002830210029317NL-OMON42480Erasmus MC, Universitair Medisch Centrum Rotterdam40